

November 29th, 2024

Announcement of Implementation of Series C Financing

ActualEyes Inc. announces the implementation of Series C financing by a domestic pharmaceutical company, bringing its accumulated fundraising to 850 million JPY. The Series C round is ongoing and expected to reach 1 billion JPY upon completion.

ActualEyes is developing the AE101 Regenerative Medicine Cell Product (Indication: bullous keratopathy*). With this funding, ActualEyes Inc. will accelerate the development of AE101. The product is currently in Phase II clinical trials in Japan, with completion planned for December 2025.

Bullous keratopathy is a disease with high medical need, and many patients await new treatment options. ActualEyes' policy is to concentrate on the development of AE101 and aim for its early commercialization.

Terminology

* Bullous keratopathy

A condition in which the corneal endothelial cells are damaged, leading to corneal edema, whitening, and cloudiness, resulting in significant vision loss. Causes include Fuchs endothelial corneal dystrophy, cataract surgery, glaucoma, and other ocular surgeries that damage the corneal endothelial cells. The current treatment is corneal transplant surgery using donor corneas.